How do you define treatment volumes for patients treated with neoadjuvant chemoimmunotherapy for resectable NSCLC who are no longer surgical candidates or decline surgery?

Good question and seeing this more routinely as there is a greater push for a neoadjuvant approach in borderline resectable surgical patients. We don't have patterns of failure data to guide this but I use the same principle/approach I use for LS-SCLC that I'm initiating at C2. Post-chemo/IO primary...